Тромбоз, гемостаз и реология

Tromboz, Gemostaz I Reologiya
scientific and practical journal

ISSN 2078–1008 (Print); ISSN 2687-1483 (online)
2023, Original papers
2023

The role of d-dimer and other coagulation parameters for diagnosing hemostatic disorders in patients with COVID-19: 616-005.6:616.151.5

Original papers
Published 2023-10-14
Elizaveta A. Bovt
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of the Russian Federation; 1 Samora Machel Str., Moscow 117997, Russia; 2Center for Theoretical Problems of Physico-Chemical Pharmacology, Russian Academy of Sciences; 30 Srednyaya Kalitnikovskaya Str., Moscow 109029, Russia;
ФГБУ «Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии имени Дмитрия Рогачева» Министерства здравоохранения Российской Федерации; Россия, 117997 Москва, ул. Саморы Машела, 1; ФГБУН «Центр теоретических проблем физико-химической фармакологии Российской академии наук»; Россия, 109029 Москва, ул. Средняя Калитниковская, 30;
https://orcid.org/0000-0003-4724-8647 (unauthenticated)

Keywords

COVID‐19
hemostasis
coagulogram
D‐dimer
  Full Text

Abstract

Summary. Introduction. Severe COVID-19 is associated with a high risk of thrombotic complications. Data from domestic and international studies indicate that screening coagulation tests are less sensitive to coagulation changes induced by COVID-19. On the other hand, the level of D-dimer is a significant indicator for predicting COVID-19 severity and the risk of fatal outcomes. Aim: to investigate hemostatic disorders in COVID-19 patients using basic screening coagulation tests and to compare the obtained data with the clinical presentation of the disease. Materials and Methods. The prospective non-randomized study involved 7 city clinical hospitals in Moscow and included 3503 patients. The endpoints of the study were hospitalization in a therapeutic department (TD) or intensive care unit (ICU) from the emergency department, as well as the presence/absence of thrombotic complications upon admission. In addition, patient hospitalization outcomes were taken into account. Results. The study results have shown that screening coagulation tests such as activated partial thromboplastin time (APTT), prothrombin time (PT), and platelet count do not significantly correlate with disease severity or the presence/absence of thrombotic complications in patients with COVID-19. On the other hand, D-dimer level significantly increased in severe cases and in patients with thrombosis. D-dimer levels > 1775 ng/mL (peak) and > 930 ng/mL (upon admission) were found to be significant prognostic indicators for assessing the risk of fatal outcomes. Conclusion. Obtained data from a large group of patients with COVID-19 highlight the significance of D-dimer in clinical practice for assessing disease severity. These data allow for a more precise identification of high risk for thrombotic complications and the likelihood of unfavorable outcomes, which may aid in timely interventions to prevent such complications.

For citation: Bovt E.A., Shakhidzhanov S.S., Filippova A.E., Ataullakhanov F.I., Rumyantsev A.G. The role of D-dimer and other coagulation parameters for diagnosing hemostatic disorders in patients with COVID-19. Tromboz, gemostaz i reologiya. 2023;(3):63–70. (In Russ.).

References

  1. Filkova A.A., Martyanov A.A., Protsenko D.N. et al. COVID-19 impact on hemostasis. Priroda. 2020;(10):3–10. (In Russ.). DOI: 10.7868/S0032874X20100014.
  2. Petrikov S. S., Popugaev K. A., Zhuravel S. V. Intensive care of patients with COVID-19. Vestnik Rossijskoj akademii nauk. 2022;92(7):678–85. (In Russ.).
  3. Evtugina N.G., Sannikova S.S., Peshkova A.D. et al. Peculiarities of blood coagulation disorders in patients with COVID-19. Terapevticheskii arkhiv. 2021;93(11):1255–63. (In Russ.). DOI: 10.26442 /00403660.2021.11.201185.
  4. Bobkova S.S., Zhukov A.A., Protsenko D.N. et al. Critical appraisal of the “cytokine storm” concept in new coronavirus disease COVID-19. Review. Vestnik intensivnoj terapii imeni A.I. Saltanova. 2021;(1):57–68. (In Russ.). DOI: 10.21320/1818-474X-2021-1-57-68.
  5. Lobastov K. V., Schastlivtsev I. V., Porembskaya O.Ya. et al. COVID-19-associated coagulopathy: review of current recommendations for diagnosis, treatment and prevention. Ambulatornaya khirurgiya. 2020;(3–4):36–51. (In Russ.). DOI: 10.21518/19 95-1477-2020-3-4-36-51.
  6. Kalinin R. E., Suchkov I. A., Agapov A. B. et al. Coagulopathy and risk factors in patients with severe COVID-19. Tromboz, gemostaz i reologiya. 2022;(4):64–74. (In Russ.). DOI: 10.25555/ THR.2022.4.1042.
  7. Samsonova M.V., Chernyaev A.L., Omarova Zh.R. et al. Features of pathological anatomy of lungs at COVID-19. Pulmonologiya. 2020;30(5): 519–32. (In Russ.). DOI: 10.18093/0869-0189-202030-5-519-532.
  8. Mehta J.L., Calcaterra G., Bassareo P.P. COVID-19, thromboembolic risk, and Virchow’s triad: lesson from the past. Clin Cardiol. 2020;43(12):1362–7. DOI: 10.1002/clc.23460.
  9. Kalinskaya A.I., Dukhin O.A., Molodtsov I.A. et al. Peculiarities of hemostasis in patients with COVID-19. Terapevticheskii arkhiv. 2022;94(7):876–83. (In Russ.). DOI: 10.26442/00403660.2022.07. 201754.
  10. Sirotkina O.V., Ermakov A.I., Gaykovaya L.B. et al. Microparticles of blood cells in patients with COVID-19 as a marker of hemostasis activation. Tromboz, gemostaz i reologiya. 2020;(4):35–40. (In Russ.). DOI: 10.25555/THR.2020.4.0943.
  11. Kishkun A.A. Clinical laboratory diagnostics: a study guide. Moscow: GEOTAR-Media, 2010. 976 pp. (In Russ.).
  12. Galstyan G. M. Coagulopathy in COVID-19. Pulmonologiya. 2020;30(5):645–57. (In Russ.). DOI: 10.18093/0869-0189-202030-5-645-657.
  13. Han H., Yang L., Liu R. et al. Prominent changes in blood coagulation of patients with SARS-CoV-2 infection. Clin Chem Lab Med. 2020;58(7):1116–20. DOI: 10.1515/cclm-2020-0188.
  14. Bulanov A.Yu., Simarova I.B., Bulanova E.L. et al. Novel coronavirus infection COVID-19: clinical and prognostic significance of plasma fibrinogen assessment. Vestnik intensivnoj terapii imeni A.I. Saltanova. 2020;(4):42–7. (In Russ.). DOI: 10.21320/1818-474 X-2020-4-42-47.
  15. Liao D., Zhou F., Luo L. et al. Haematological characteristics and risk factors in the classification and prognosis evaluation of COVID-19: a retrospective cohort study. Lancet Haematol. 2020;7(9): e671-e678. DOI: 10.1016/S2352-3026(20)30217-9.
  16. An O. I., Martyanov A. A., Stepanyan M. G. et al. Platelets in COVID-19: “innocent by-standers” or active participants? Voprosy gematologii/onkologii i immunopatologii v pediatrii. 2021;20(1):184– 91. (In Russ.). DOI: 10.24287/1726-1708-2021-20-1-184-191.
  17. Zhang L., Yan X., Fan Q. et al. D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19. J Thromb Haemost. 2020;18(6):1324–9. DOI: 10.1111/jth.14859.
  18. Zhan H., Chen H., Liu C. et al. Diagnostic value of D-dimer in COVID-19: a meta-analysis and meta-regression. Clin Appl Thromb Hemost. 2021;27:10760296211010976. DOI: 10.1177/10760296211010976.
  19. Interim guidelines. Prevention, diagnosis and treatment of novel coronavirus infection (COVID-19). Version 5 (02.04.2020). Moscow: Ministerstvo zdravoohraneniya Rossijskoj Federacii, 2020. 112 рp. (In Russ.). Available at: https://onkoyar.ru/ wp-content/uploads/2020/04/Metodicheskie-rekomendatsiiCOVID-19-ver.5.pdf. [Accessed: 10.05.2023].
  20. Girard P., Sanchez O., Leroyer C. et al.; Evaulation du Scanner Spiralé dans l’EmboliePulmonaire Study Group. Deep venous thrombosis in patients with acute pulmonary embolism: prevalence, risk factors, and clinical significance. Chest. 2005;128(3):1593– 600. DOI: 10.1378/chest.128.3.1593.
  21. Suh Y.J., Hong H., Ohana M. et al. Pulmonary embolism and deep vein thrombosis in COVID-19: a systematic review and meta-analysis. Radiology. 2021;298(2): E70–E80. DOI: 10.1148/ radiol.2020203557.
  22. Tan B.K., Mainbourg S., Friggeri A. et al. Arterial and venous thromboembolism in COVID-19: a study-level meta-analysis. Thorax. 2021;76(10):970–9. DOI: 10.1136/thoraxjnl-2020-215383.
  23. Seregina E. A., Koltsova E. M., Ataullakhanov F. I., Rumyantsev A.G. Laboratory parameters of hemostasis in patients with COVID-19. Voprosy gematologii/onkologii i immunopatologii v pediatrii. 2021;20(3):147–55. (In Russ.). DOI: 10.24287/1726-1708-202 1-20-3-147-155.
  24. Martyanov A.A., Boldova A.E., Stepanyan M.G. et al. Longitudinal multiparametric characterization of platelet dysfunction in COVID-19: effects of disease severity, anticoagulation therapy and inflammatory status. Thromb Res. 2022;211:27–37. DOI: 10.1016/j. thromres.2022.01.013.
  25. Len P., Iskakova G., Sautbayeva Z. et al. Meta-analysis and systematic review of coagulation disbalances in COVID-19: 41 studies and 17,601 patients. Front Cardiovasc Med. 2022;9:794092. DOI: 10.3389/fcvm.2022.794092.